Xencor Inc (XNCR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Xencor Inc (XNCR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH138584D
  • |
  • Pages: 57
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Xencor Inc (Xencor) focuses on the discovery and development of engineered monoclonal antibodies to treat life threatening diseases. Its pipeline product portfolio includes XmAb14045, XmAb 5871, XmAb 7195 and XmAb13676. The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. Xencor licensed its XmAb technology to pharmaceutical and biotechnology companies such as Boehringer Ingelheim International GmBH, CSL Limited, Janssen R&D, LLC (Janssen), Merck, Sharp and Dohme and Alexion Pharmaceuticals, Inc. for their research and development activities. Xencor is headquartered in Monrovia, California, the US.

Xencor Inc (XNCR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Xencor Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Xencor Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Xencor Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Xencor Raises US$7.6 Million In Venture Financing 11

Partnerships 11

Selexis Enters into Agreement with Xencor 11

Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 12

Licensing Agreements 13

Amgen Enters into Licensing Agreement with Xencor 13

Novartis Enters into Licensing Agreement with Xencor 14

Xencor Enters into Licensing Agreement with Receptor Logic 15

Xencor Enters into Licensing Agreement with Novo Nordisk 16

Xencor Enters Into Licensing Agreement With Merck 17

Xencor Enters Into Licensing Agreement With CSL For Xtend Technology 18

Xencor Enters into Licensing Agreement with Alexion Pharma 19

sAber Bioscience Enters Into Licensing Agreement With Xencor For XmAb Technology 20

FPRT Bio Enters into Licensing Agreement with Xencor for XPro1595 21

Equity Offering 22

Xencor Raises USD126.5 Million in Public Offering of Shares 22

Xencor Raises USD123 Million in Public Offering of Shares 23

Xencor Completes IPO For US$80.5 Million 25

Xencor Inc-Key Competitors 27

Key Employees 28

Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

May 09, 2017: Xencor Reports First Quarter 2017 Financial Results 30

Feb 28, 2017: Xencor Reports Fourth Quarter and Full Year 2016 Financial Results 32

Nov 02, 2016: Xencor Reports Third Quarter 2016 Financial Results 35

Aug 02, 2016: Xencor Reports Second Quarter 2016 Financial Results 37

May 02, 2016: Xencor Reports First Quarter 2016 Financial Results 39

Mar 07, 2016: Xencor Reports Fourth Quarter and Full Year 2015 Financial Results 41

Corporate Communications 44

Mar 06, 2017: Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders 44

Jan 11, 2016: Xencor Announces Change to Board of Directors 45

Product News 46

05/18/2016: Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference 46

Clinical Trials 48

Nov 13, 2016: Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting 48

Nov 11, 2016: Xencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and Additional Bispecific Antibody Candidates at Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting 50

Oct 03, 2016: Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease to be presented at American College of Rheumatology (ACR) 2016 Annual Meeting 51

Sep 15, 2016: Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195 52

Sep 12, 2016: Xencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute Myeloid Leukemia and Other CD123-Expressing Hematologic Malignancies 53

Mar 07, 2016: Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus 54

Other Significant Developments 55

Jun 28, 2016: Xencor Provides Updates on Lead Programs and Reviews Bispecific Oncology Partnership; Announces Expansion of Bispecific Oncology Pipeline at Analyst Day 55

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57

List of Figures

Xencor Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Xencor Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Xencor Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Xencor Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Xencor Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Xencor Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Xencor Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Xencor Raises US$7.6 Million In Venture Financing 11

Selexis Enters into Agreement with Xencor 11

Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies 12

Amgen Enters into Licensing Agreement with Xencor 13

Novartis Enters into Licensing Agreement with Xencor 14

Xencor Enters into Licensing Agreement with Receptor Logic 15

Xencor Enters into Licensing Agreement with Novo Nordisk 16

Xencor Enters Into Licensing Agreement With Merck 17

Xencor Enters Into Licensing Agreement With CSL For Xtend Technology 18

Xencor Enters into Licensing Agreement with Alexion Pharma 19

sAber Bioscience Enters Into Licensing Agreement With Xencor For XmAb Technology 20

FPRT Bio Enters into Licensing Agreement with Xencor for XPro1595 21

Xencor Raises USD126.5 Million in Public Offering of Shares 22

Xencor Raises USD123 Million in Public Offering of Shares 23

Xencor Completes IPO For US$80.5 Million 25

Xencor Inc, Key Competitors 27

Xencor Inc, Key Employees 28

Xencor Inc, Other Locations 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Xencor Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16648
Site License
USD 500 INR 33295
Corporate User License
USD 750 INR 49943

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com